Resident memory T cells, critical components in tumor immunology

Area of Science:

• Immunology
• Cancer Biology
• Cellular Immunology

Background:

• CD8⁺ T lymphocytes are primary anti-tumor effector cells, with cancer immunotherapies aiming to enhance cytotoxic T lymphocytes (CTLs).
• Tissue-resident memory T (T_RM) cells are a distinct CD8⁺ T cell subset residing in tissues, lacking recirculation.
• T_RM cells possess unique transcription factor profiles (Runx3⁺, Notch⁺, Hobit⁺, Blimp1⁺, BATF⁺, AHR⁺, EOMES^neg, Tbet^low) and express CD103, CD49a, and CD69 for tissue retention.

Purpose of the Study:

• To elucidate the role of T_RM cells in anti-tumor immunity and their potential as therapeutic targets.
• To investigate the mechanisms of T_RM cell retention and function within solid tumors.
• To explore the correlation between T_RM cell infiltration and clinical outcomes in cancer patients.

Main Methods:

• Characterization of T_RM cell surface markers (CD103, CD49a, CD69) and transcription factor profiles.
• Analysis of the CD103-E-cadherin interaction's role in T_RM cell localization and cytotoxic granule release.
• Assessment of T_RM cell cytotoxic features (granzyme B, IFNγ, TNFα) and their response to environmental factors (TGF-β, IL-33, IL-15).

Main Results:

• T_RM cells are retained in non-lymphoid tissues, including tumors, via CD103-E-cadherin interactions, facilitating close contact with malignant cells.
• T_RM cells exhibit potent cytotoxic activity, enhanced by factors like IFNγ and TNFα, and are crucial for controlling tumor growth in preclinical models.
• Infiltration of T_RM cells into human cancers, such as lung cancer, significantly correlates with improved clinical outcomes, independent of overall CD8⁺ T cell counts.

Conclusions:

• T_RM cells are critical components of tumor immune surveillance, directly impacting tumor growth and patient prognosis.
• The expression of checkpoint receptors (PD-1, CTLA-4, Tim-3) on T_RM cells suggests their involvement in immune evasion and potential responsiveness to checkpoint inhibitors.
• Targeting T_RM cell induction through cancer vaccines or immunotherapies may be vital for enhancing treatment efficacy against various cancers.